about
Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Study exploring depression and cardiovascular diseases amongst Arabic speaking patients living in the State of Qatar: Rationale and methodologyObesity pharmacotherapy: current perspectives and future directionsCardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesityThe role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.Altered gene expression in pulmonary tissue of tryptophan hydroxylase-1 knockout mice: implications for pulmonary arterial hypertension.Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart diseaseHigh-fat and obesogenic diets: current and future strategies to fight obesity and diabetes.Pharmacologic treatment options for obesity: what is old is new again.The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens.Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice.Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.The scoring bias in reverse docking and the score normalization strategy to improve success rate of target fishing.Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (THIN) database.Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations.Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.Lorcaserin for the treatment of obesityExploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates.A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.Metabolites in safety testing.Filamin-a-related myxomatous mitral valve dystrophy: genetic, echocardiographic and functional aspects.Cellular mechanisms in mitral valve disease.Serotonin paracrine signaling in tissue fibrosisDistinct signaling pathways activated by "extracellular" and "intracellular" serotonin in heart valve development and disease.Reducing the risk of obesity: defining the role of weight loss drugs.Update on obesity pharmacotherapy.Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Pathophysiology of Aortic Stenosis and Mitral Regurgitation.Predicting in vivo safety characteristics using physiochemical properties and in vitro assays.A happy valve in a happy patient? Serotonergic antidepressants and the risk of valvular heart disease (SERVAL). A case-control study.Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors.5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'.Inhibition of cocaine and 3,4-methylenedioxypyrovalerone (MDPV) self-administration by lorcaserin is mediated by 5-HT2C receptors in rats.The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.Improving amphetamine therapeutic selectivity: N,N-dimethyl-MTA has dopaminergic effects and does not produce aortic contraction.Trichloroethylene perturbs HNF4a expression and activity in the developing chick heart.
P2860
Q24595389-76FDC010-317C-4DD7-9906-FA3EB3060872Q26825298-CC5C6FE4-CDE9-4426-8C2D-AAC7AB036BCBQ26828559-34E3909E-1D44-4B79-9E5B-712D75CB1981Q33572190-0145157C-EED5-4B9D-A451-9D6C81704F55Q33598487-EF4077A8-DBB6-4859-AA8F-12F0CE870D02Q33750634-EAB91EEB-1ADD-45FD-B2E0-1F01F66892F9Q33862778-770DE5A4-3F2C-4185-A798-4316EF0E82DCQ33863285-5FC52440-77F0-40CB-8A43-70D87AB24C71Q34212924-3BA16A05-145A-4CEB-B1A1-C6E7A7490527Q34341681-B62D75D8-BA8A-4BE4-A6F6-1D30029417D2Q34546304-15EA10A0-EE02-4EE7-BA50-4FC027C978D0Q34659424-436AF93B-83A9-42F1-AC4A-1186A74101B2Q35096627-C043CF34-4C23-480F-9D53-F7268B23DE5CQ35640425-1B11448C-7CAD-45F8-8C8A-AC2AD9DDAC4EQ36280059-CF511570-4CDA-40F4-9579-A7A9992EFF49Q36336069-7850833F-2536-419B-8046-73C5DEA30B97Q36350604-E3E1752C-D33A-4FF5-9943-E84435546ED1Q36975405-1047D217-1621-47D3-B53C-141E8D26CFEFQ37172259-568F15A5-E765-4D32-8D76-B1DC63277EF7Q37649640-2C382F8B-E947-4F27-945D-4290B31FE961Q37705731-6FC766AC-54EE-4595-B76F-E005BADA5CA9Q37707718-799277E7-7BCE-42E7-8006-FA5D7EB4E3F3Q37810131-55D29A40-CADF-456F-8AD5-7B27EE7ECB4EQ37902988-EE9FD0BE-9CA6-440A-AACE-9CB821EB01ABQ37926555-021501D1-DCD7-46BE-A440-721A8E63C6ACQ38049023-DB3BF919-ADA4-44E0-A84D-243C86510FB3Q38100690-E6F04CC2-E06B-4B26-883D-02B63796DF51Q38109836-BC8281D8-958F-4EA7-BC96-92907E9EF7B9Q38196951-3A9F16A1-071B-4AE6-9807-56D6BEDB472FQ38219851-B9E7860B-6382-45E1-9837-DB7BA860CAD8Q38758765-171E8FE5-B30D-4380-BED8-FAA8E2DD2E7DQ39390979-E8747A72-D219-47A2-B8A1-44D6E4ACE002Q39481089-A1F7C880-D4C3-49C3-9C8E-221EA151F1BEQ40802093-A40128F7-BB25-404C-9DB4-7C24AAFA3752Q41538383-7481C5D8-106C-4EA3-939E-1CCC14F64040Q42905649-8D69355E-242D-4657-83BF-87E1AC9EDB8DQ47348330-690F9E51-63C2-4A1B-8831-A3782FCF9E8DQ47677518-16C2DFDC-D2E9-452A-91CF-12C34D8AB534Q48821854-BE2E4107-15BA-4343-9EF9-DD6B13328248Q50152905-987DA5F2-7CD2-4B2C-9E30-CC19A8E1E4A9
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Serotonergic drugs and valvular heart disease
@ast
Serotonergic drugs and valvular heart disease
@en
Serotonergic drugs and valvular heart disease
@nl
type
label
Serotonergic drugs and valvular heart disease
@ast
Serotonergic drugs and valvular heart disease
@en
Serotonergic drugs and valvular heart disease
@nl
prefLabel
Serotonergic drugs and valvular heart disease
@ast
Serotonergic drugs and valvular heart disease
@en
Serotonergic drugs and valvular heart disease
@nl
P2860
P1476
Serotonergic drugs and valvular heart disease
@en
P2093
Michael H Baumann
Richard B Rothman
P2860
P304
P356
10.1517/14740330902931524
P407
P577
2009-05-01T00:00:00Z